10x Genomics launched Atera, a new in situ spatial biology platform aimed at whole-transcriptome mapping with single-cell sensitivity at scale. The company said Atera is engineered to work across both fresh-frozen and FFPE tissue and to remove tradeoffs that have historically limited spatial scale, sensitivity, or gene selection. 10x positioned Atera as enabling large-scale whole-transcriptome studies in discovery and translational research, with sample data ties to the June Lab at the University of Pennsylvania and DKFZ. The release also included market guidance implications, as 10x forecast dimmed spatial biology sales while Atera rolls out and said the new platform is expected to contribute to revenue in Q4.